arrow
B

Brendan Reardon

Harvard University
H指数:26
被引数:9,593

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes

不同内源性逆转录病毒在透明细胞肾细胞癌的突变亚型中表达,并与改善的临床结局相关

2026-08-010
OAAI
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer

多模态循环游离DNA分析预测去甲长春花碱在转移性去势抵抗性前列腺癌中的疗效反应

2026-04-280
OAAI
A context-augmented large language model for accurate precision oncology medicine recommendations

一种用于精准肿瘤学医学推荐的上下文增强大型语言模型

2026-01-150
OAAI
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

疗效、安全性及预测性生物标志物:nab-paclitaxel联合pembrolizumab治疗激素受体阳性乳腺癌的随机试点试验

2025-11-280
OAAI
ESMO Recommendations on clinical reporting of genomic test results for solid cancers

ESMO关于实体癌基因组检测结果临床报告的建议

2024-11-010
OAAI
The Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network directly engage patient participants in genomics research
2023-04-041
PRE
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma
2023-04-040
PRE
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology

通过分子肿瘤学年鉴将分子概况整合到临床框架中,以前瞻性地指导精确肿瘤学

2021-09-3019
OA
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
2021-09-2128
OAAI
Discovery and Features of an Alkylating Signature in Colorectal Cancer
2021-06-1744
OAAI
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
2021-03-11118
OA
Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma
2020-12-0238
OAAI